Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Aromatase inhibitors and bone.

Richard Eastell1

  • 1The Academic Unit of Bone Metabolism, Musculoskeletal Section, School of Medicine and Biomedical Sciences, University of Sheffield, Sheffield, UK. r.eastell@sheffield.ac.uk

The Journal of Steroid Biochemistry and Molecular Biology
|July 24, 2007
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

An index of net bone formation relative to resorption is associated with incident fracture during the menopause transition and postmenopause.

JBMR plus·2026
Same author

Efficacy, pharmacodynamics, pharmacokinetics, safety, and immunogenicity of Bmab 1000 vs reference denosumab: 78-wk results from a randomized, double-blind, multicenter, parallel-arm Phase 3 trial (DEVOTE) in women with postmenopausal osteoporosis.

JBMR plus·2026
Same author

Natural history of thyroid function in ageing: an individual participant data analysis of 137 488 participants from 31 prospective cohort studies.

The lancet. Diabetes & endocrinology·2026
Same author

Improvement of Bone Mineral Density in Patients with Type 1 Gaucher Disease Treated with Velaglucerase Alfa: Results from Clinical Studies.

Journal of clinical medicine·2026
Same author

Monte Carlo Resampling Validates Use of Bone Mineral Density Change as Surrogate to Replace Fracture in Future Randomized Trials of Osteoporosis Treatments: Results From SABER.

Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research·2026
Same author

Growth differentiation factor 15 and the risk of hip fracture in older adults.

JBMR plus·2026
Same journal

L-Arginine Improves Prenatal and Pre-pubertal Codeine-Induced Steroidogenesis Deregulation by Suppressing Oxidative Stress-Dependent Signaling in Male Wistar Rats.

The Journal of steroid biochemistry and molecular biology·2026
Same journal

Discovery of 17-imidazo[1,2-a]pyridinyl-3α-hydroxy-5α-androstanes (17IPAs) as novel potent positive allosteric modulators of the GABA<sub>A</sub> receptor: Synthesis, in vitro and in silico studies.

The Journal of steroid biochemistry and molecular biology·2026
Same journal

Androgen receptor as therapeutic indicator for LAR-positive triple-negative breast cancer: Preclinical and clinical assessment.

The Journal of steroid biochemistry and molecular biology·2026
Same journal

The 24,25(OH)<sub>2</sub>D<sub>3</sub>-TLCD3B signaling complex and reproductive function in mice and men.

The Journal of steroid biochemistry and molecular biology·2026
Same journal

Testosterone and epitestosterone differentially regulate UDP-glucuronosyltransferases (UGT) activity.

The Journal of steroid biochemistry and molecular biology·2026
Same journal

Interferon-gamma-inducible protein-10 is associated to increased primary bile acids and fibrosis in primary sclerosing cholangitis.

The Journal of steroid biochemistry and molecular biology·2026
See all related articles

Aromatase inhibitors lower estrogen, accelerating bone loss and fracture risk, especially in older women with low bone density. Bisphosphonates may prevent this bone loss.

Area of Science:

  • Oncology
  • Endocrinology
  • Osteoporosis Research

Background:

  • Aromatase inhibitors (AIs) are crucial in breast cancer treatment.
  • AI therapy significantly reduces estrogen levels.
  • Estrogen deficiency is a known risk factor for bone loss and osteoporosis.

Purpose of the Study:

  • To investigate the impact of AI-induced estrogen decrease on bone remodeling.
  • To assess the consequent risk of bone loss and fractures.
  • To explore potential preventive strategies for AI-associated bone complications.

Main Methods:

  • Review of existing literature on AI therapy and bone metabolism.
  • Analysis of bone remodeling markers in patients undergoing AI treatment.
  • Correlation of bone mineral density with fracture incidence in this cohort.

Related Experiment Videos

Main Results:

  • AI use accelerates bone remodeling.
  • This leads to increased bone loss.
  • Fracture risk is elevated, particularly in postmenopausal women with pre-existing low bone mineral density.

Conclusions:

  • AI-induced estrogen suppression accelerates bone loss and increases fracture risk.
  • Postmenopausal osteoporosis treatments, especially bisphosphonates, show promise in mitigating AI-related bone loss.
  • Further research is warranted to confirm the efficacy of bisphosphonates in this context.